1
|
Hoang VT, Verma D, Godavarthy PS, Llavona P, Steiner M, Gerlach K, Michels BE, Bohnenberger H, Wachter A, Oellerich T, Müller-Kuller U, Weissenberger E, Voutsinas JM, Oehler VG, Farin HF, Zörnig M, Krause DS. The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia. Leukemia 2019; 33:1700-1712. [PMID: 30635626 DOI: 10.1038/s41375-018-0358-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 11/28/2018] [Accepted: 12/05/2018] [Indexed: 01/20/2023]
Abstract
The transcriptional regulator far upstream element binding protein 1 (FUBP1) acts as an oncoprotein in solid tumor entities and plays a role in the maintenance of hematopoietic stem cells. However, its potential function in leukemia is unknown. In murine models of chronic (CML) and acute myeloid leukemia (AML) induced by BCR-ABL1 and MLL-AF9, respectively, knockdown of Fubp1 resulted in prolonged survival, decreased numbers of CML progenitor cells, decreased cell cycle activity and increased apoptosis. Knockdown of FUBP1 in CML and AML cell lines recapitulated these findings and revealed enhanced DNA damage compared to leukemia cells expressing wild type FUBP1 levels. FUBP1 was more highly expressed in human CML compared to normal bone marrow cells and its expression correlated with disease progression. In AML, higher FUBP1 expression in patient leukemia cells was observed with a trend toward correlation with shorter overall survival. Treatment of mice with AML with irinotecan, known to inhibit topoisomerase I and FUBP1, significantly prolonged survival alone or in combination with cytarabine. In summary, our data suggest that FUBP1 acts as cell cycle regulator and apoptosis inhibitor in leukemia. We demonstrated that FUBP1 might play a role in DNA repair, and its inhibition may improve outcome in leukemia patients.
Collapse
Affiliation(s)
- Van T Hoang
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - Divij Verma
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | | | - Pablo Llavona
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - Marlene Steiner
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - Katharina Gerlach
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - Birgitta E Michels
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany.,Faculty of Biological Sciences, Goethe University Frankfurt, Frankfurt, Germany
| | - Hanibal Bohnenberger
- Universitätsmedizin Göttingen, Institute of Pathology, Georg-August-Universität, 37075, Göttingen, Germany
| | - Astrid Wachter
- Universitätsmedizin Göttingen, Department of Medical Statistics, Georg-August-Universität, 37075, Göttingen, Germany
| | - Thomas Oellerich
- German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany.,University Hospital Frankfurt, Department of Medicine II, Hematology/Oncology, Frankfurt, Germany
| | - Uta Müller-Kuller
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - Eva Weissenberger
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - Jenna M Voutsinas
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Biostatistics, Seattle, WA, USA
| | - Vivian G Oehler
- Fred Hutchinson Cancer Research Center, Clinical Research Division, Division of Hematology, University of Washington Medical Center, Seattle, WA, USA
| | - Henner F Farin
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Martin Zörnig
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany
| | - Daniela S Krause
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany. .,German Cancer Consortium (DKTK), Heidelberg, Germany. .,German Cancer Research Center (DKFZ), Heidelberg, Germany. .,Faculty of Medicine, Johann Wolfgang Goethe University, Frankfurt, Germany.
| |
Collapse
|
2
|
Brendel C, Rothe M, Santilli G, Charrier S, Stein S, Kunkel H, Abriss D, Müller-Kuller U, Gaspar B, Modlich U, Galy A, Schambach A, Thrasher AJ, Grez M. Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease. HUM GENE THER CL DEV 2018; 29:69-79. [PMID: 29664709 DOI: 10.1089/humc.2017.245] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Chronic granulomatous disease (CGD) is a debilitating primary immunodeficiency affecting phagocyte function due to the absence of nicotinamide dinucleotide phosphate (NADPH) oxidase activity. The vast majority of CGD patients in the Western world have mutations within the X-linked CYBB gene encoding for gp91phox (NOX2), the redox center of the NADPH oxidase complex (XCGD). Current treatments of XCGD are not entirely satisfactory, and prior attempts at autologous gene therapy using gammaretrovirus vectors did not provide long-term curative effects. A new strategy was developed based on the use of the lentiviral vector G1XCGD expressing high levels of the gp91phox transgene in myeloid cells. As a requisite for a clinical trial approval, standardized non-clinical studies were conducted in vitro and in mice in order to evaluate the pharmacodynamics and biosafety of the vector and the biodistribution of G1XCGD-transduced cells. Transduced CD34+ cells derived from XCGD patients engrafted and differentiated similarly to their non-transduced counterparts in xenograft mouse models and generated therapeutically relevant levels of NADPH activity in myeloid cells expressing gp91phox. Expression of functional gp91phox in hematopoietic cells did not affect their homing properties, which engrafted at high levels in mice. Extensive in vitro and in vivo genotoxicity studies found no evidence for adverse mutagenesis related to vector treatment. These studies paved the way for the approval of clinical trials in Europe and in the United States for the treatment of XCGD patients with G1XCGD gene-modified autologous hematopoietic cells.
Collapse
Affiliation(s)
- Christian Brendel
- 1 Institute for Tumor Biology and Experimental Therapy , Georg-Speyer-Haus, Frankfurt, Germany .,2 Division of Hematology/Oncology, Boston Children's Hospital , Boston, Massachusetts.,3 Harvard Medical School , Boston, Massachusetts.,4 Pediatric Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts.,5 Harvard Stem Cell Institute, Harvard University , Boston, Massachusetts
| | - Michael Rothe
- 6 Hannover Medical School, Institute of Experimental Hematology , Hannover, Germany
| | - Giorgia Santilli
- 7 UCL Great Ormond Street Institute of Child Health, and Great Ormond Street Hospital for Children NHS Trust London , United Kingdom
| | | | - Stefan Stein
- 1 Institute for Tumor Biology and Experimental Therapy , Georg-Speyer-Haus, Frankfurt, Germany
| | - Hana Kunkel
- 1 Institute for Tumor Biology and Experimental Therapy , Georg-Speyer-Haus, Frankfurt, Germany
| | - Daniela Abriss
- 1 Institute for Tumor Biology and Experimental Therapy , Georg-Speyer-Haus, Frankfurt, Germany
| | - Uta Müller-Kuller
- 1 Institute for Tumor Biology and Experimental Therapy , Georg-Speyer-Haus, Frankfurt, Germany
| | - Bobby Gaspar
- 7 UCL Great Ormond Street Institute of Child Health, and Great Ormond Street Hospital for Children NHS Trust London , United Kingdom
| | - Ute Modlich
- 6 Hannover Medical School, Institute of Experimental Hematology , Hannover, Germany .,9 Research Group Gene Modification in Stem Cells , Paul-Ehrlich-Institute, Langen, Germany
| | | | - Axel Schambach
- 2 Division of Hematology/Oncology, Boston Children's Hospital , Boston, Massachusetts.,6 Hannover Medical School, Institute of Experimental Hematology , Hannover, Germany .,10 Hannover Medical School , Cluster of Excellence REBIRTH, Hannover, Germany
| | - Adrian J Thrasher
- 7 UCL Great Ormond Street Institute of Child Health, and Great Ormond Street Hospital for Children NHS Trust London , United Kingdom
| | - Manuel Grez
- 1 Institute for Tumor Biology and Experimental Therapy , Georg-Speyer-Haus, Frankfurt, Germany
| |
Collapse
|
3
|
Schanda J, Lee CW, Wohlan K, Müller-Kuller U, Kunkel H, Coco IQL, Stein S, Metz A, Koch J, Lausen J, Platzbecker U, Medyouf H, Gohlke H, Heuser M, Eder M, Grez M, Scherr M, Wichmann C. Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization. Haematologica 2017; 102:e170-e174. [PMID: 28154087 DOI: 10.3324/haematol.2016.161570] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Julia Schanda
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Chun-Wei Lee
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany
| | - Katharina Wohlan
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany
| | - Uta Müller-Kuller
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany.,German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Hana Kunkel
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Isabell Quagliano-Lo Coco
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany.,German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Stefan Stein
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Alexander Metz
- Institute for Pharmaceutical and Medicinal Chemistry, Department of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, Germany
| | - Joachim Koch
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Jörn Lausen
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Uwe Platzbecker
- Department of Hematology, Medical Clinic and Polyclinic I, University Hospital Carl Gustav Carus, Dresden, Germany
| | - Hind Medyouf
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Holger Gohlke
- Institute for Pharmaceutical and Medicinal Chemistry, Department of Mathematics and Natural Sciences, Heinrich Heine University Düsseldorf, Germany
| | - Michael Heuser
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany
| | - Matthias Eder
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany
| | - Manuel Grez
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Michaela Scherr
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany
| | - Christian Wichmann
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany.,Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, Ludwig-Maximilian University Hospital, Munich, Germany
| |
Collapse
|
4
|
Gerlach K, Müller-Kuller U, Thalheimer F, Rieger M, Krause D, Zörnig M. Friend or foe? the fuse-binding protein 1 (FUBP1) as an essential regulator of HSC self-renewal and a potential oncogene in leukemia development. Exp Hematol 2016. [DOI: 10.1016/j.exphem.2016.06.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Ackermann M, Müller-Kuller U, Merkert S, Martin U, Grez M, Schambach A, Moritz T, Lachmann N. 234. Efficient Generation of Stable Genetically Modified Human iPSC-Derived Macrophages for Innovative Gene and Cell Therapeutic Strategies. Mol Ther 2016. [DOI: 10.1016/s1525-0016(16)33043-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Coutandin D, Osterburg C, Srivastav RK, Sumyk M, Kehrloesser S, Gebel J, Tuppi M, Hannewald J, Schäfer B, Salah E, Mathea S, Müller-Kuller U, Doutch J, Grez M, Knapp S, Dötsch V. Quality control in oocytes by p63 is based on a spring-loaded activation mechanism on the molecular and cellular level. eLife 2016; 5. [PMID: 27021569 PMCID: PMC4876613 DOI: 10.7554/elife.13909] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Accepted: 03/28/2016] [Indexed: 01/07/2023] Open
Abstract
Mammalian oocytes are arrested in the dictyate stage of meiotic prophase I for long
periods of time, during which the high concentration of the p53 family member TAp63α
sensitizes them to DNA damage-induced apoptosis. TAp63α is kept in an inactive and
exclusively dimeric state but undergoes rapid phosphorylation-induced tetramerization
and concomitant activation upon detection of DNA damage. Here we show that the TAp63α
dimer is a kinetically trapped state. Activation follows a spring-loaded mechanism
not requiring further translation of other cellular factors in oocytes and is
associated with unfolding of the inhibitory structure that blocks the tetramerization
interface. Using a combination of biophysical methods as well as cell and ovary
culture experiments we explain how TAp63α is kept inactive in the absence of DNA
damage but causes rapid oocyte elimination in response to a few DNA double strand
breaks thereby acting as the key quality control factor in maternal reproduction. DOI:http://dx.doi.org/10.7554/eLife.13909.001 The irradiation and chemotherapy drugs that are used to destroy cancer cells also
damage healthy cells. Germ cells – from which egg cells and sperm cells develop – are
particularly vulnerable as they contain sensitive quality control mechanisms that
kill any cell that contain damaged DNA. Consequently, after surviving cancer many
patients are confronted with infertility. A protein called p63, which is closely related to another protein that suppresses the
formation of tumors, plays an essential role in detecting and responding to DNA
damage. In immature egg cells (also known as oocytes), p63 mostly exists in an
inactive form. The protein then switches to an active form when DNA damage is
detected to trigger the process of cell self-destruction. Now, Coutandin, Osterburg et al. have performed a range of biochemical, biophysical
and cell culture experiments to study how p63 is kept in its inactive form in the
oocytes of mice. The experiments showed that in the inactive form, the two ends of
the protein form a sheet that closes a key site on the protein and prevents it from
changing into its active form. However, this closed form can be thought of as being
like a spring-loaded trap – it doesn’t take much energy to spring the trap and open
the protein into its active form. Once this change has occurred, it is
irreversible. Coutandin, Osterburg et al. also found that the oocytes of mice already contain all
the proteins necessary to activate p63. This means that once the switch to the active
form is triggered there is no delay waiting for other proteins to be made, which
makes oocytes extremely sensitive to DNA damage. Further work is now needed to
investigate the exact molecular mechanisms behind the activation of p63. DOI:http://dx.doi.org/10.7554/eLife.13909.002
Collapse
Affiliation(s)
- Daniel Coutandin
- Institute of Biophysical Chemistry, Goethe University, Frankfurt, Germany.,Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.,Cluster of Excellence Macromolecular Complexes, Goethe University, Frankfurt, Germany
| | - Christian Osterburg
- Institute of Biophysical Chemistry, Goethe University, Frankfurt, Germany.,Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.,Cluster of Excellence Macromolecular Complexes, Goethe University, Frankfurt, Germany
| | - Ratnesh Kumar Srivastav
- Institute of Biophysical Chemistry, Goethe University, Frankfurt, Germany.,Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.,Cluster of Excellence Macromolecular Complexes, Goethe University, Frankfurt, Germany
| | - Manuela Sumyk
- Institute of Biophysical Chemistry, Goethe University, Frankfurt, Germany.,Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.,Cluster of Excellence Macromolecular Complexes, Goethe University, Frankfurt, Germany
| | - Sebastian Kehrloesser
- Institute of Biophysical Chemistry, Goethe University, Frankfurt, Germany.,Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.,Cluster of Excellence Macromolecular Complexes, Goethe University, Frankfurt, Germany
| | - Jakob Gebel
- Institute of Biophysical Chemistry, Goethe University, Frankfurt, Germany.,Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.,Cluster of Excellence Macromolecular Complexes, Goethe University, Frankfurt, Germany
| | - Marcel Tuppi
- Institute of Biophysical Chemistry, Goethe University, Frankfurt, Germany.,Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.,Cluster of Excellence Macromolecular Complexes, Goethe University, Frankfurt, Germany
| | - Jens Hannewald
- MS-DTB-C Protein Purification, Merck KGaA, Darmstadt, Germany
| | - Birgit Schäfer
- Institute of Biophysical Chemistry, Goethe University, Frankfurt, Germany.,Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.,Cluster of Excellence Macromolecular Complexes, Goethe University, Frankfurt, Germany
| | - Eidarus Salah
- Nuffield Department of Medicine, Structural Genomics Consortium, University of Oxford, Oxford, United Kingdom
| | - Sebastian Mathea
- Nuffield Department of Medicine, Structural Genomics Consortium, University of Oxford, Oxford, United Kingdom
| | | | - James Doutch
- ISIS Neutron and Muon Source, Rutherford Appleton Laboratory, Didcot, United Kingdom
| | | | - Stefan Knapp
- Nuffield Department of Medicine, Structural Genomics Consortium, University of Oxford, Oxford, United Kingdom.,Institute for Pharmaceutical Chemistry, Goethe University, Frankfurt, Germany.,Buchmann Institute for Molecular Life Science, Goethe University, Frankfurt, Germany
| | - Volker Dötsch
- Institute of Biophysical Chemistry, Goethe University, Frankfurt, Germany.,Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt, Germany.,Cluster of Excellence Macromolecular Complexes, Goethe University, Frankfurt, Germany
| |
Collapse
|
7
|
Müller-Kuller U, Ackermann M, Kolodziej S, Brendel C, Fritsch J, Lachmann N, Kunkel H, Lausen J, Schambach A, Moritz T, Grez M. A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells. Nucleic Acids Res 2015; 43:1577-92. [PMID: 25605798 PMCID: PMC4330381 DOI: 10.1093/nar/gkv019] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Epigenetic silencing of transgene expression represents a major obstacle for the efficient genetic modification of multipotent and pluripotent stem cells. We and others have demonstrated that a 1.5 kb methylation-free CpG island from the human HNRPA2B1-CBX3 housekeeping genes (A2UCOE) effectively prevents transgene silencing and variegation in cell lines, multipotent and pluripotent stem cells, and their differentiated progeny. However, the bidirectional promoter activity of this element may disturb expression of neighboring genes. Furthermore, the epigenetic basis underlying the anti-silencing effect of the UCOE on juxtaposed promoters has been only partially explored. In this study we removed the HNRPA2B1 moiety from the A2UCOE and demonstrate efficient anti-silencing properties also for a minimal 0.7 kb element containing merely the CBX3 promoter. This DNA element largely prevents silencing of viral and tissue-specific promoters in multipotent and pluripotent stem cells. The protective activity of CBX3 was associated with reduced promoter CpG-methylation, decreased levels of repressive and increased levels of active histone marks. Moreover, the anti-silencing effect of CBX3 was locally restricted and when linked to tissue-specific promoters did not activate transcription in off target cells. Thus, CBX3 is a highly attractive element for sustained, tissue-specific and copy-number dependent transgene expression in vitro and in vivo.
Collapse
Affiliation(s)
- Uta Müller-Kuller
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| | - Mania Ackermann
- RG Reprogramming and Gene Therapy, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany Institute of Experimental Hematology, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany
| | - Stephan Kolodziej
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| | - Christian Brendel
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| | - Jessica Fritsch
- RG Reprogramming and Gene Therapy, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany Institute of Experimental Hematology, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany
| | - Nico Lachmann
- RG Reprogramming and Gene Therapy, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany Institute of Experimental Hematology, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany
| | - Hana Kunkel
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| | - Jörn Lausen
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| | - Axel Schambach
- Institute of Experimental Hematology, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Thomas Moritz
- RG Reprogramming and Gene Therapy, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany Institute of Experimental Hematology, Hannover Medical School, Hannover, Lower Saxony, 30625, Germany
| | - Manuel Grez
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Hessen, 60596, Germany
| |
Collapse
|
8
|
Brendel C, Goebel B, Daniela A, Brugman M, Kneissl S, Schwäble J, Kaufmann KB, Müller-Kuller U, Kunkel H, Chen-Wichmann L, Abel T, Serve H, Bystrykh L, Buchholz CJ, Grez M. CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells. Mol Ther 2014; 23:63-70. [PMID: 25189742 DOI: 10.1038/mt.2014.173] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Accepted: 08/25/2014] [Indexed: 11/09/2022] Open
Abstract
Gene therapy for hematological disorders relies on the genetic modification of CD34(+) cells, a heterogeneous cell population containing about 0.01% long-term repopulating cells. Here, we show that the lentiviral vector CD133-LV, which uses a surface marker on human primitive hematopoietic stem cells (HSCs) as entry receptor, transfers genes preferentially into cells with high engraftment capability. Transduction of unstimulated CD34(+) cells with CD133-LV resulted in gene marking of cells with competitive proliferative advantage in vitro and in immunodeficient mice. The CD133-LV-transduced population contained significantly more cells with repopulating capacity than cells transduced with vesicular stomatitis virus (VSV)-LV, a lentiviral vector pseudotyped with the vesicular stomatitis virus G protein. Upon transfer of a barcode library, CD133-LV-transduced cells sustained gene marking in vivo for a prolonged period of time with a 6.7-fold higher recovery of barcodes compared to transduced control cells. Moreover, CD133-LV-transduced cells were capable of repopulating secondary recipients. Lastly, we show that this targeting strategy can be used for transfer of a therapeutic gene into CD34(+) cells obtained from patients suffering of X-linked chronic granulomatous disease. In conclusion, direct gene transfer into CD133(+) cells allows for sustained long-term engraftment of gene corrected cells.
Collapse
Affiliation(s)
- Christian Brendel
- 1] Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany [2] Current address: Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Benjamin Goebel
- Department of Medicine, Hematology/Oncology, JW-Goethe-University, Frankfurt/M, Germany
| | - Abriss Daniela
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Martijn Brugman
- Department of Immunohematology and Blood Transfusion (IHB) Leiden University Medical Center, Leiden, Netherlands
| | - Sabrina Kneissl
- 1] Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany [2] Current address: Division of Haematology/Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany
| | - Joachim Schwäble
- Institute for Transfusion Medicine and Immune Hematology, Clinics of the Johann Wolfgang Goethe University, German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen, Frankfurt am Main, Hessen, Germany
| | - Kerstin B Kaufmann
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Uta Müller-Kuller
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Hana Kunkel
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| | - Linping Chen-Wichmann
- 1] Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany [2] Current address: Experimental Cell Therapy and Hematology, Department of Transfusion Medicine, Cell Therapy and Haemostaseology, Ludwig Maximilian University Hospital Munich, Munich, Germany
| | - Tobias Abel
- Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany
| | - Hubert Serve
- Department of Medicine, Hematology/Oncology, JW-Goethe-University, Frankfurt/M, Germany
| | - Leonid Bystrykh
- Department of Cell Biology, University Medical Center Groningen, Groningen, Netherlands
| | - Christian J Buchholz
- Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany
| | - Manuel Grez
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany
| |
Collapse
|
9
|
Stein S, Scholz S, Schwäble J, Sadat MA, Modlich U, Schultze-Strasser S, Diaz M, Chen-Wichmann L, Müller-Kuller U, Brendel C, Fronza R, Kaufmann KB, Naundorf S, Pech NK, Travers JB, Matute JD, Presson RG, Sandusky GE, Kunkel H, Rudolf E, Dillmann A, von Kalle C, Kühlcke K, Baum C, Schambach A, Dinauer MC, Schmidt M, Grez M. From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease. HUM GENE THER CL DEV 2013; 24:86-98. [PMID: 23845071 DOI: 10.1089/humc.2013.019] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by impaired antimicrobial activity in phagocytic cells. As a monogenic disease affecting the hematopoietic system, CGD is amenable to gene therapy. Indeed in a phase I/II clinical trial, we demonstrated a transient resolution of bacterial and fungal infections. However, the therapeutic benefit was compromised by the occurrence of clonal dominance and malignant transformation demanding alternative vectors with equal efficacy but safety-improved features. In this work we have developed and tested a self-inactivating (SIN) gammaretroviral vector (SINfes.gp91s) containing a codon-optimized transgene (gp91(phox)) under the transcriptional control of a myeloid promoter for the gene therapy of the X-linked form of CGD (X-CGD). Gene-corrected cells protected X-CGD mice from Aspergillus fumigatus challenge at low vector copy numbers. Moreover, the SINfes.gp91s vector generates substantial amounts of superoxide in human cells transplanted into immunodeficient mice. In vitro genotoxicity assays and longitudinal high-throughput integration site analysis in transplanted mice comprising primary and secondary animals for 11 months revealed a safe integration site profile with no signs of clonal dominance.
Collapse
Affiliation(s)
- Stefan Stein
- Institute for Biomedical Research, Georg-Speyer-Haus, 60596 Frankfurt, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|